Nobio Ltd has received a $205,000 grant from the Israel Innovation Authority to develop and manufacture solutions to prevent, treat, and otherwise assist in managing the COVID-19 outbreak, according to the company.
The funds will support the development and manufacture of personal protective equipment (PPE) and long-acting surface coating incorporating Nobio’s antimicrobial technology, which uses patented nanoparticles that transform common materials into antimicrobial materials indefinitely.
Nobio’s Infinix products for dental restorations, which use these nanoparticles, received clearance from the US Food and Drug Administration last year with a commercial launch planned for the second half of 2020. The program funded by the grant focuses on two applications.
The first is PPE with priority for antiviral facemasks, given the primary infection route of the novel coronavirus, and nonwoven fabrics, which are commonly used for protective wear.
The second application is surface coatings, with long-acting, universal protection to prevent transmission of pathogenic microorganisms such as the novel coronavirus.
Both applications will incorporate Nobio’s antimicrobial technology, which uniquely provides long-lasting, potent, and broad-spectrum activity, the company says.
Nobio adds that it also is working with market-leading manufacturers to produce the final products with the antimicrobial particles, which the company will manufacture and supply. Further, Nobio says it has begun to scale up production capacity for its particles to meet the expected increase in demand.
“Its universal action, compatibility with many materials, and long action make Nobio’s technology well suited for multiple uses relevant for dealing with this pandemic,” said Yoram Ashery, Nobio’s CEO. “We prioritized these applications to see that our proposed solutions reach the market as soon as possible.”